-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The net result for the period of deducting operating expenses from operating revenues.
-
Summary
-
GT Biopharma, Inc. quarterly/annual Operating Income (Loss) history and growth rate from 2010 to 2023.
- GT Biopharma, Inc. Operating Income (Loss) for the quarter ending June 30, 2024 was -$3.91M, a 7.87% decline year-over-year.
- GT Biopharma, Inc. Operating Income (Loss) for the twelve months ending June 30, 2024 was -$13.3M, a 33.9% increase year-over-year.
- GT Biopharma, Inc. annual Operating Income (Loss) for 2023 was -$13.6M, a 36.1% increase from 2022.
- GT Biopharma, Inc. annual Operating Income (Loss) for 2022 was -$21.3M, a 63% increase from 2021.
- GT Biopharma, Inc. annual Operating Income (Loss) for 2021 was -$57.5M, a 750% decline from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Annual (USD)
Operating Income (Loss), YoY Annual Growth (%)